95
1.
Адаскевич В.П. Диагностические индексы в дерматологии. М.: 2004: 107-109.
2.
Бишарова А.С. Псориаз у детей. Лечащий врач. 2006;9:14-17.
3.
Мурашкин Н.Н., Мазитова Л.П., Намазова Л.С. Особенности ангиогенеза и обоснование
патогенетической терапии у детей, страдающих псориазом. Вестник дерматологии и венерологии.
2009;1:81-87.
4.
Приятинская В.А., Карякина Л.А., Приятинская А.Б. и др. Псориаз. Дифференциальная диагностика.
Принципы лечения. Клиническая дерматология и венерология. 2011;1:83-90.
5.
Рахматов А.Б., Мирхамидова Н.В. Эпидемиология псориаза в Узбекистане и перспективы его лечения.
Дерматовенерология и эстетическая медицина. 2009;1:8-10.
6.
Шадиев Х.К., Маннанов А.М., Хаитов К.Н. Нарушения психоэмоциональной сферы у детей, больных
псориазом. Дерматовенерология и эстетическая медицина. 2009;1:48-51.
7.
Islam M.T., Paul H.K., Zakaria S.M. et al. Epidemiological determinants of psoriasis. Mymensingh Med J.
2011;20(1):9-15.
8.
Richert B., Andre J. Nail disorders in children: diagnosis and management. Am J Clin Dermatol.
2011;12(2):101 -112.
9.
Wu J.J., Helen Black M., Porter A.N. et al. Low prevalence of psoriasis among children and adolescents in
large multiethnic cohort in southen California. J Am Acad Dermatol. 2011;1(10):27-30.
10.
189. Krueger J.C. 2005. The immunologic basis for the treatment of psoriasis' with new biologic agents. J.
Am. Acad. Dermatol. Vol. 46. P. 1-23.
11.
West J., Ogston S., Foerster J. Safety and efficacy of methotrexate in psoriasis: ameta-analysis of published
trials. PLoS ONE 2016; 11 (5): e0153740.
12.
Gisondi P., Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug
Design, Development and Therapy 2016: 10; 1763-1770.
Бабабекова Н.Б., Ходжаева С.М. Рахманкулова С.А.
ПСОРИАЗ КАСАЛЛИГИ БИЛАН КАСАЛЛАНГАН БЕМОР БОЛАЛАРГА СКИН-КАП ДОРИ
ВОСИТАСИНИ МАХАЛЛИЙ КУЛЛАНИЛИШИ
Псориаз касаллиги билан хасталанган 1-17 ёшгача
110 та нафар болаларда СКИН-КАП дори
воситасини махаллий даво воситаси сифатида
Bababekova N.B., Xodjaeva S.M. Rakhmankulova S.A.
THE EFFECTIVENESS OF THE DRUG SKIN-KAP IN CHILDREN WITH PSORIASIS WITH
LOCAL THERAPY
Based on a survey and follow-up of 110 patients with
psoriasis in children aged 1 to 17 years, it has been
found that the inclusion of the preparation of the SKIN-
KAP, intended for local use, the complex has anti-
inflammatory therapy, keratoplastic properties and can
achieve a positive therapeutic effect.
Bababekova N.B., Rakhmankulova S.A.
FEATURES OF IMMUNOLOGICAL CHARACTERISTICS OF CHILDREN WITH
PSORIASIS
Tashkent pediatric medical institute
According to modern concepts, psoriasis is a
multifactorial disease, which developmentis closely
related to genetic defects of the immune response and
the negative effects of adverse environmental
influences. It has been established that the effect of
these factors determines the rate of development of
psoriasis, especially in young children. Psoriasis is one
of the most important medical and social problems, as
Литература
ананавий
даво
чораси
билан
биргаликда
кулланилиши, кератопластик ва яллигланиш
жараёнига ижобий терапевтик натижа бер.
П
ос
вя
щ
ае
тс
я
к
1
00
-л
ет
и
ю
с
о
дн
я
р
ож
де
н
и
я
п
ро
ф
ес
со
р
а
К
ар
и
м
а
С
ул
ей
м
ан
ов
и
ч
а
С
ул
ей
м
ан
ов
а
ПЕДИАТРИЯ
96
the prevalence of the disease is steadily increasing.
Existing epidemiological studies indicate a high
prevalence of psoriasis in children, which varies in
different countries from 10 to 30%. According to
various studies, psoriasis, which began in childhood,
continues to persist in adults in 40-60% of cases [ 1].
The purpose of the study:
to evaluate the
immunological features in children suffering from
psoriasis.
Materials and methods:
There were 72
children with psoriasis aged from 1 month to 18 years
under our supervision; 52 of them were examined
during exacerbation and 20 during remission of the
underlying disease. 61 patients aged 3 months to 18
years (4.8±3.65 years) with psoriasis (main group) and
11 children (age 5.2±1.9 years) without signs
To assess the cytokine profile, the content of
TNF-a, IL-4 and IL-6 (pg/ml) was determined in
dynamics during the first three days of the exacerbation
period and 1 month after the start of the course of
treatment.The cytokine level was determined by
enzyme immunoassay. The studies were conducted
during the acute period of exacerbation of the disease.
Descriptive statistics of qualitative features are
represented by absolute and relative frequencies (in
percentages). The critical value of the significance level
was considered to be p = 0.05.The research and
interpretation of the results were carried out in
accordance with the domestic industry standard. The
study included 40 patients aged 1 to 18 years.
Results:
As a result of the study, it was
revealed that in children with psoriasis and without
signs of allergic inflammation, almost all of the
interleukins we studied may be present. However, their
presence and individual level values have a different
range (Table 1).
Changes in the level of proinflammatory
cytokine TNF-a in the blood serum were not so definite
and pronounced, depending on the stage of the
process.A significant increase in its level was observed
in severe psoriasis both during exacerbation of the
(comparison group) who were treated in the
dermatology department of the Tashkent Pediatric
Medical Institute clinic were examined. There were 46
boys (63.8%) and 26 girls (36.2%) among the studied
children.
We investigated the level of pro (TNF-a) and
anti-inflammatory (IL-4, IL-6) cytokines in the blood
serum of patients with psoriasis. To determine the
cytokine level in the blood serum, blood samples were
taken from a finger or from a vein in dry plastic tubes.
After the treatment of the blood clot, the blood sample
was centrifuged at 2500 g, the serum was taken using a
pipette, which was used for analysis (the serum was
subjected to a single freezing at a temperature from - 18
° C to -24 ° C and stored for no more than a month
before the analysis).
disease and during remission, as well as during
remission in patients with moderate course of the
disease. With a mild course of psoriasis, its level did not
differ from the control values.
Indicators of IgE level depending on severity:
in patients with mild psoriasis Ig E 381.5±140.5 IU/ml,
with moderate severity 294,754±69.86 IU/ml, in
patients with severe psoriasis Ig E level
481,749±138.76 IU/ml. Thus, the severity of allergic
manifestations does not depend on the level of Ig E -
with a mild degree, the amount of Ig E is higher than
with a moderate degree of severity. Apparently, the
severity of psoriasis is determined not by the level of Ig
E in the blood serum, but by the influence of triggers on
the development of allergic inflammation.
The cytokine profile of IL-4 and IL-6 was
studied in 38 patients in the first three days from the
moment of admission and 1 month after the start of
treatment - on the 35-40 day, depending on the severity
of psoriasis. Clinically, the patients differed in the
severity of itching from insignificant in mild to painful
with sleep disturbance in severe.
The level of cytokines in patients with varying
degrees of severity during exacerbation in patients is
shown in Figure 1.
П
ос
вя
щ
ае
тс
я
к
1
00
-л
ет
и
ю
с
о
дн
я
ро
ж
де
н
и
я
п
ро
ф
ес
со
р
а
К
ар
и
м
а
С
ул
ей
м
ан
ов
и
ч
а
С
ул
ей
м
ан
ов
а
97
As can be seen from Figure 1, the level of IL- 4
in serum with mild psoriasis is slightly lower than with
moderate and severe, but does not significantly differ.
The level of IL-2 in severe psoriasis is lower than in
patients with mild and moderate severity, but also does
not significantly differ. We assume that the absence of
a statistically significant difference may be due to a
small sample size. The level of IL-6 production did not
depend on the severity of psoriasis.
To assess the cytokine profile, we analyzed
similar indicators of IL-4 and IL-6 levels in children
without signs of allergy of the same age and gender. It
is important to note that the level of IL-4 in patients with
psoriasis was higher than in the group without allergies,
but significant differences (p<0.02) were found only in
patients with moderate severity of psoriasis. The IL-6
content was also higher in patients with psoriasis, but
we did not find significant differences with the control
group.
Results
Thus, it was found that the levels of cytokines
in the blood serum reflect the current state of the
immune system of psoriasis patients. Summing up the
study of the cytokine content in the blood serum of
patients with psoriasis of varying severity, it can be
concluded that there is a tendency to increased
production of anti-inflammatory cytokines (IL-4 and
IL-6) during exacerbation of the disease and increased
synthesis of pro-inflammatory cytokines (TNF-a)
during remission.This may indicate activation of
cytokine production of both Th2 and Th17 types. In
general, the polarization of Th2 and Th17 towards an
increase in functional activity in the acute period
corresponds to the classical ideas about the
immunopathogenesis of psoriasis.
List of references
1.
Adaskevich V.P. Diagnosticheskiye indeksi v dermatologii. М.: 2004: 107-109.
2.
Bisharova A.S. Psoriaz u detey. Lechashiy vrach 2006;9:14-17.
3.
Murashkin N.N., Mazitova L.P., Namazova L.S.Osobennosti angiogeneza I obosnovaniye patogeneticheskoy
terapii u detey, stradayushix psoriazom. VestnikdermatologiiIvenerologii. 2009;1:81-87.
4.
Priyatinskaya V.A., Karyakina L.A., Priyatinskaya A.B. andother. Psoriaz. Differencial nayadiagnostika.
Prinsipilecheniya. KlinicheskayadermatologiyaIvenerologiya 2011;1:83-90.
5.
Rahmatov A.B., Mirkhamidova N.V. Epidemiologiy apsoriazav Uzbekistane Iperspektiviyegolecheniya.
Dermatovenerologiyaiesteticheskayamedicina 2009;1:8-10.
6.
Vinogradova T.V., et al. Sovremennayaocenkacitokinovogostatusadeteypriatopicheskomdermatite.
Rossiyskiyvestnikpediatrii 59.1 (2014).
Dynamics of skin manifestations in children with psoriasis in varying
degrees of severity
mild
moderate
severe
■
Row
77
89
56
П
ос
вя
щ
ае
тс
я
к
1
00
-л
ет
и
ю
с
о
дн
я
ро
ж
де
н
и
я
п
ро
ф
ес
со
р
а
К
ар
и
м
а
С
ул
ей
м
ан
ов
и
ч
а
С
ул
ей
м
ан
ов
а
severe
■
Row
ПЕДИАТРИЯ
98
7.
Shadiev H.K., Mannanov A.M., Hayitov K.N. Narusheniyepsihoemocialnoysferiudetey, bolnixpsoriazom.
Dermatovenerologiyaiesteticheskayamedicina 2009; 1:48-51.
8.
Islam M.T., Paul H.K., Zakaria S.M. et al. Epidemiological determinants of psoriasis. Mymensingh Med J.
2011;20(1):9 -15.
9.
Richert B., Andre J. Nail disorders in children: diagnosis and management. Am J Clin Dermatol.
2011;12(2):101-112.
10.
Wu J.J., Helen Black M., Porter A.N. et al. Low prevalence of psoriasis among children and adolescents in
large multiethnic cohort in southen California. J Am AcadDermatol. 2011;1(10):27-30.
11.
189. Krueger J.C. 2005. The immunologic basis for the treatment of psoriasis' with new biologic agents // J.
Am. Acad. Dermatol. Vol. 46. P. 1-23.
12.
West J., Ogston S., Foerster J. Safety and efficacy of methotrexate in psoriasis: ameta-analysis of published
trials. PLoS ONE 2016; 11 (5): e0153740.
13.
Gisondi P., Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.
DrugDesign, DevelopmentandTherapy 2016: 10; 1763 - 1770.
14.
Gorlanov I.A. Detskayadermatovenerologiya. Uchebnik. 2017.С.207-223.
15.
Goryachkina L.A., Kashkina K.P., M: Miklosh; Klinicheskayaallergologiya I immunologiya.
Rukovostvodlyapraktikuyushihvrachey. 2009
16.
Асадов, Д. А., А. Б. Яркулов, and Д. И. Ахмедова. "Анализ причин младенческой смертности в
Республике Узбекистан и пути ее снижения." Педиатрия 1 (1999): 10-16.
17.
Акрамова, Хурсаной Абдумаликовна, Дилорам Илхамовна Ахмедова, and Зарина Руслановна
Хайбуллина. "АУТОАНТИТЕЛА, ПРОФИЛИ ИММУНОРЕАКТИВНОСТИ И ИХ СВЯЗЬ С
ЗАБОЛЕВАНИЯМИ." Journal of cardiorespiratory research 1.1 (2022): 13-18.
18.
Akcura, F., D. Ahmedova, and P. Menlikulov. "Health For All: A Key Goal for Uzbekistan in the New
Millennium." Tashkent: United Nations Development Programme (2006).
П
ос
вя
щ
ае
тс
я
к
1
00
-л
ет
и
ю
с
о
дн
я
ро
ж
де
н
и
я
п
ро
ф
ес
со
р
а
К
ар
и
м
а
С
ул
ей
м
ан
ов
и
ч
а
С
ул
ей
м
ан
ов
а
